Zafgen, now part of Larimar Therapeutics, is a biopharmaceutical company dedicated to developing innovative therapies for rare metabolic diseases. The company primarily targets conditions such as Prader-Willi syndrome and other genetic disorders that result in severe metabolic dysfunction. Operating in the highly specialized field of rare disease treatment, Zafgen serves a niche market of patients with limited therapeutic options. The business model revolves around the research, development, and commercialization of novel drug candidates. Revenue is generated through the successful development and subsequent licensing or sale of these therapies to larger pharmaceutical companies or directly to healthcare providers. Zafgen's strategic focus on rare diseases allows it to benefit from orphan drug designations, which can provide market exclusivity and financial incentives.

Keywords: biopharmaceutical, rare diseases, metabolic disorders, Prader-Willi syndrome, genetic disorders, drug development, orphan drugs, niche market, therapeutic innovation, healthcare.